tiprankstipranks
Advertisement
Advertisement
Omeros reports Q1 adjusted EPS (24c), consensus (28c)
PremiumThe FlyOmeros reports Q1 adjusted EPS (24c), consensus (28c)
1M ago
Omeros options imply 10.8% move in share price post-earnings
Premium
The Fly
Omeros options imply 10.8% move in share price post-earnings
1M ago
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
Premium
The Fly
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
1M ago
Omeros reports Q4 EPS $1.22, consensus 36c
PremiumThe FlyOmeros reports Q4 EPS $1.22, consensus 36c
2M ago
Omeros Corporation (OMER) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Omeros Corporation (OMER) Q4 Earnings Cheat Sheet
3M ago
Omeros: YARTEMLEA Cash Flows Funding High-Upside OncotoX-AML Pipeline, Supporting Buy Rating and $40 Target
Premium
Ratings
Omeros: YARTEMLEA Cash Flows Funding High-Upside OncotoX-AML Pipeline, Supporting Buy Rating and $40 Target
4M ago
Omeros call volume above normal and directionally bullish
PremiumThe FlyOmeros call volume above normal and directionally bullish
6M ago
Omeros call volume above normal and directionally bullish
Premium
The Fly
Omeros call volume above normal and directionally bullish
6M ago
D. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating
Premium
The Fly
D. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100